tbuckley/cabot-search huggingface dataset:
537 - The distribution of thyroid disease by age in pediatric vitiligo
Authors: Nanette B Silverberg
Journal: British Journal of Dermatology (2024)

Abstract Background Thyroid disease is a comorbid autoimmune disorder linked to vitiligo. Objective To identify the age distribution of pediatric vitiligo cases in order to understand when screening should begin. Methods An IRB-exempt survey of pediatric vitiligo patients. Results Thyroid disease was reported in 14 children out of 205 children who specifically responded regarding presence of thyroid disease, Of the 14 children reporting sex with thyroid disease, 12 were female (85.7%) and 2 were unknown. Race/ ethnicity included 8 Caucasian (57.1%), Indian 2 (14.2%), Unknown 3 (21.4%), and Black 1 (7.1 %). Average age of diagnosis of thyroid disease in vitiligo patients (self-reported) was 9.7 years (Range 6 years-18 years). Limitations The survey design has limitations, and the number of reported cases is low overall. Conclusion and Relevance Thyroid disease appears uncommon as a comorbidity in pre-school children. All races may be at risk. The role of family history is unknown. Presentation is almost exclusively in girls. This data suggests that screening can be reserved for females and guided by age and symptoms.
518 - Interaction of sleep disturbance and nocturnal scratch in atopic dermatitis patients
Authors: Christos Alexopoulos, Alia Kassim, Yiorgos Christakis, Junrui Di, Kevin Thomas, Madisen Wicker, Nina Shaafi Kabiri, Walter Lehan, Sanford Auerbach, Carrie Northcott, John G Samuelsson
Journal: British Journal of Dermatology (2024)

Abstract Introduction/Background Itch, scratch and poor sleep are often cited as key symptoms of Atopic Dermatitis (AD). Although approximately 10-41% of children and 7-48% of adults in the general population experience sleep disturbances, this figure climbs to 47-80% in children with AD and 33-90% in adults with AD (Bawany et al., 2021). While great effort has been done to characterize and validate nocturnal scratch and sleep, the relationship between the two remains poorly characterized. Objectives We hypothesize that nocturnal scratch is the reason for the sleep disturbances in patients with AD. Literature suggests that these symptoms are linked, albeit not necessarily causal. Here we investigate the interaction between nocturnal scratch events and sleep disturbances in study participants with AD compared to a healthy cohort. Methods Patients with AD (n=185) and without AD (n=40) aged between 2 to 75 years were recruited across three different studies. Study participants spent the night in a qualified sleep lab while being under observation with thermal videography and polysomnography (PSG). The thermal videography was annotated for both scratch and non-scratch movements by two trained annotators independently with any conflicts being resolved by an arbitrator. The PSG was scored by a credentialed technologist in 30-s epochs per revised American Academy of Sleep Medicine scoring guidelines. The study participants also wore a wrist-worn accelerometer on both the left and right wrists. Results It was noted that sleep disturbances were associated with the observed scratch events, and that the temporal relationship between sleep disturbance and scratching seemed to differ between the AD and healthy cohorts. Surprisingly, however, it was also noted that within a few study participants with AD, scratch events occurred while the patient was in stable REM sleep, most often in the children with AD. Further investigation will provide additional information as to whether this was an artifact or in fact a true observation. We also present an overview of sleep, as well as nocturnal scratch and non-scratch movements in the AD and healthy cohorts, noting specifically how the behaviors differ between the groups, and over the course of the sleep opportunity, across sleep stages and sleep cycles, as well as their relationships to sleep disturbances. Conclusions Nocturnal scratching is often associated with sleep disturbances in AD; however, the causality is not always clear. Moreover, in some cases scratching was observed during stable REM sleep in AD, an observation that requires further investigation.
Racial and ethnic disparities in genomic testing among lung cancer patients: a systematic review
Authors: Clare Meernik, Yadurshini Raveendran, Michaela Kolarova, Fariha Rahman, Ebunoluwa Olunuga, Emmery Hammond, Akhilesh Shivaramakrishnan, Steph Hendren, Hayden B Bosworth, Devon K Check, Michelle Green, John H Strickler, Tomi Akinyemiju
Journal: JNCI Journal of the National Cancer Institute (2024)

Racial and ethnic disparities in genomic testing could exacerbate disparities in access to precision cancer therapies and survival-particularly in the context of lung cancer where genomic testing has been recommended for the past decade. However, prior studies assessing disparities in genomic testing have yielded mixed results.
548 - Tralokinumab improves signs and symptoms of moderate-to-severe atopic dermatitis in patients aged 12 years and older with and without atopic comorbidities
Authors: Amy S Paller, Weily Soong, Mark Boguniewicz, Bob Geng, Jacob P Thyssen, Aldana Rosso, Louise Steffensen, Shannon Schneider, Andreas Wollenberg
Journal: British Journal of Dermatology (2024)

Abstract Introduction/Background Atopic dermatitis (AD) is an inflammatory skin disease associated with atopic comorbidities, including asthma, food allergy, hay fever, and allergic conjunctivitis. Tralokinumab, a high-affinity monoclonal antibody that specifically targets IL-13, is indicated for the treatment of moderate-to-­severe AD. Objectives To assess the impact of atopic comorbidities on the efficacy and safety of tralokinumab vs. placebo for moderate-to-­severe AD in patients age ≥12 years. Methods This post-hoc analysis presents data from the adult trials ECZTRA 1 and 2 (NCT03131648 and NCT03160885 pooled; 300 mg tralokinumab every 2 weeks [Q2W] vs. placebo) and ECZTRA 3 (NCT03363854; 300 mg tralokinumab Q2W vs. placebo, both plus TCS as needed), and the ECZTRA 6 adolescent trial (NCT03526861; pooled 150 mg and 300 mg tralokinumab Q2W vs. placebo). Tralokinumab-treated patients received a loading dose. Proportion of patients achieving IGA 0/1 and EASI-75 at Week 16 according to patient-reported current or past atopic comorbidity are presented as observed regardless of rescue medication use; missing data were imputed as non-responders. Results In total 2,223 patients were included across four trials. Among patients in ECZTRA 1 and 2, 50.5% reported history of asthma, 38.5% food allergy, 53.8% hay fever, and 33.5% allergic conjunctivitis, while 19.8% reported no atopic comorbidities and 79.3% reported ≥1 atopic comorbidity. Proportions of patients in ECZTRA 3 and 6 reporting history of atopic comorbidities were largely similar, although more adolescent patients reported food allergy. In all subgroups at Week 16, higher proportions of patients receiving tralokinumab vs. placebo achieved EASI-75. In ECZTRA 1 and 2, response rates among patients in each subgroup were asthma: 35.3% vs. 12.8%, food allergy: 33.2% vs. 14.7%, hay fever: 36.8% vs. 16.5%, allergic conjunctivitis: 34.8% vs. 12.7%, none: 34.6% vs. 20.5%; and ≥1 atopic comorbidity: 35.5% vs. 15.2% (P&amp;lt;0.05 for all). A similar pattern of response was observed in ECZTRA 3 and 6, and for IGA 0/1 across trials. EASI-75 response rates for tralokinumab-treated patients were consistent across patients with different numbers of atopic comorbidities. Safety across subgroups was consistent with the safety profile of tralokinumab observed overall in adults and adolescents. Conclusions 16 weeks of tralokinumab treatment improved AD signs and symptoms in adult and adolescent patients with and without atopic comorbidities, regardless of type or number of atopic comorbidities. The safety profile of tralokinumab was consistent between patients with and without atopic comorbidities.
502 - Efficacy and safety of upadacitinib through 140 weeks in adolescents and adults with moderate-to-severe atopic dermatitis: phase 3 randomized clinical trial results
Authors: Jonathan I Silverberg, Emma Guttman-Yassky, Eric L Simpson, Kim A Papp, Andrew Blauvelt, Chia-Yu Chu, H Chih-ho Hong, Linda F Stein Gold, Thomas Bieber, Kenji Kabashima, David Rosmarin, Amy Gamelli, Brian Calimlim, Namita Vigna, Xiaofei Hu, Yang Yang, Xiaoqiang Wu, Xiaohong Huang, Smitha Suravaram, Henrique D Teixeira, Eliza Raymundo, Alan D Irvine
Journal: British Journal of Dermatology (2024)

Abstract Introduction &amp; Objectives Upadacitinib (UPA) is an oral Janus kinase 1 (JAK1) inhibitor approved in multiple countries for the treatment of adolescents and adults with moderate-to-severe atopic dermatitis (AD). Here, we present the efficacy and safety of UPA administered over 140 weeks in an ongoing randomized, double-blinded, multicenter phase 3 study (Measure Up 1, NCT03569293). Materials &amp; Methods Patients (12–75 years) with moderate-to-severe AD were randomized 1:1:1 to receive UPA 15 mg (UPA15), UPA 30 mg (UPA30), or placebo (PBO) once daily at baseline. At week 16, PBO-treated patients were re-randomized 1:1 to receive UPA15 (PBO/UPA15) or UPA30 (PBO/UPA30) once daily. Co-primary endpoints were the proportion of patients achieving ≥75% reduction in EASI (EASI 75) from baseline and vIGA-AD of clear (0) or almost clear (1) with ≥2 grades of reduction from baseline (vIGA-AD 0/1) at week 16. A meaningful improvement in itch, defined as a ≥4-point reduction in Worst Pruritus Numeric Rating Scale (ΔWP-NRS≥4), was assessed among patients with baseline WP-NRS≥4. All efficacy endpoints were summarized using the Observed Cases (OC) approach, and no missing data imputation was applied. Safety was assessed by monitoring of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs), and treatment-emergent adverse events of special interest (AESI), which were analysed as exposure-adjusted rates per 100 patient-years (PY). Results Efficacy results were sustained up to week 140 since week 16. Proportions of patients in the UPA15 (205), UPA30 (206), PBO/UPA15 (91), and PBO/UPA30 (94) groups achieving EASI 75 at week 140 were 88.8% (182), 90.3% (186), 83.5% (76), and 89.4% (84), respectively, and for vIGA-AD 0/1 was 63.4% (130), 65.5% (135), 60.4% (55), and 75.5% (71), respectively. Proportions of patients achieving an improvement (reduction) in WP-NRS≥4 from baseline at week 140 were 68.0% (136), 70.5% (146), 71.3% (62), and 81.3% (74) respectively. Overall, the rates of AESIs were similar across treatment groups, which aligned with prior reports at earlier time points. Both UPA15 and UPA30 were well-tolerated in all patients, and no new safety signals were observed compared to the known safety profile of UPA. Data from two additional pivotal studies will be available at the time of presentation. Conclusion In this interim analysis, sustained skin clearance and itch and a consistent safety profile were observed with UPA 15 mg and UPA 30 mg across 140 weeks in adolescent and adult patients with moderate-to-severe AD.
506 - Dupilumab is efficacious in patients with prurigo nodularis regardless of history of atopic comorbidities: pooled results from two phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Authors: Brian S Kim, Margarida Gonçalo, Tsukasa Ugajin, Amy Praestgaard, Melanie Makhija, Joseph Zahn, Ashish Bansal, Simmi Wiggins
Journal: British Journal of Dermatology (2024)

Abstract Introduction Prurigo nodularis (PN) is a chronic inflammatory skin condition characterized by severely itchy skin nodules. Nearly half of affected adult patients have a history of (or current) atopic comorbidity, such as atopic dermatitis (AD). Objective To report the efficacy and safety of dupilumab in patients with PN with or without history of atopic comorbidities, in a pre-specified analysis of pooled data from two phase 3 trials. Method In the randomized, double-blind, placebo-controlled, 24-week studies, LIBERTY-PN PRIME (NCT04183335) and PRIME2 (NCT04202679), adults with PN inadequately controlled by topical prescription therapies, were randomized 1:1 to dupilumab 300 mg every 2 weeks or matched placebo. Atopic patients were defined as patients with a physician-documented history, or current diagnosis, of at least one of the following atopic comorbidities: AD, allergic rhinitis/rhinoconjunctivitis, asthma, or food allergy. Efficacy was assessed from baseline to Week 24 through the Worst Itch Numerical Rating Scale (WI-NRS; 0–10), and the Investigator’s Global Assessment for PN-Stage score (IGA PN-S; 0–4). Results 311 patients were randomized (dupilumab n=153, atopic/non-atopic N=67/86; placebo n=158, atopic/non-atopic N=68/90). At Week 24, significantly more atopic and non-atopic dupilumab-treated patients achieved a ≥4-point improvement in WI-NRS (58.2%/59.3%), and an IGA PN-S score of 0 or 1 (52.2%/41.9%) vs placebo (20.6%/17.8% [nominal P&amp;lt;0.0001/P&amp;lt;0.0001] and 16.2%/17.8% [nominal P&amp;lt;0.0001/P=0.0005], respectively). The proportion of patients achieving concomitant ≥4-point improvement in WI-NRS and IGA PN-S score of 0 or 1 was higher for both dupilumab-treated atopic and non-atopic patients (37.3%/33.7%) vs placebo (7.4%/10.0% [nominal P=0.0057/P&amp;lt;0.007]). Overall safety was consistent with the known dupilumab safety profile, with no remarkable differences between atopic and non-atopic patients. Conclusion Dupilumab treatment improves itch and skin lesions in PN patients with and without a history of atopic comorbidities, indicating that underlying type 2 inflammation is present in patients with PN regardless of their history of atopic comorbidities.
553 - Tralokinumab real-world patient-reported outcomes in moderate-to-severe atopic dermatitis adult patients in the United States: 6-month interim analysis
Authors: Peter Lio, Yestle Kim, Sanjeev Balu, Halley Costantino, Dawn Bates, Cassandra Rene, Amanda Lopez, Jennifer Soung
Journal: British Journal of Dermatology (2024)

Abstract Introduction/Background Tralokinumab, an IL-13 targeted biologic approved in the United States (US) for adult patients with moderate-to-severe atopic dermatitis (AD), improved patient-reported outcomes (PROs) in clinical trials and after 4 weeks of use in the real-world setting. Objectives This 6-month interim analysis evaluated the real-world impact of tralokinumab on PROs in adult patients. Methods This is an interim analysis of an ongoing 52-week patient survey study enrolling US AD patients from the AdbryTM AdvocateTM Program. Patients completed the baseline survey close to tralokinumab initiation. Data on demographics and PROs including weekly itch numeric rating scale (NRS), eczema-related weekly sleep NRS, Dermatology Life Quality Index (DLQI), and Treatment Satisfaction Questionnaire for Medication (TSQM-9) were collected. Percent and absolute changes from baseline to 6 months of treatment were calculated. Outcomes are stratified by previous dupilumab use. The percentage of patients experiencing minimal clinically important difference (MCID) was also calculated for itch NRS (3-point reduction) and DLQI (4-point reduction). Results As of May 2023, 102 patients completed baseline, 1-month, and 6-month surveys. Of these, 59.8% were female, mean age was 44.2 years (SD=15.7), 82.4% were white, and 85.3% had private insurance. 84.3% were previously treated with topical corticosteroids (TCS) and 52.9% were dupilumab-experienced patients. Over 6 months, there was an improvement in the mean sleep interference NRS (40%), average weekly itch NRS (39%), worst weekly itch NRS (33%), PO-SCORAD (37%), and DLQI (52%). There were improvements in mean TSQM-9 global satisfaction (11.06 points), TSQM-9 convenience (3.92 points), and TSQM-9 effectiveness (14.60 points) scores. Median MCIDs were met by 57.1% on the sleep interference NRS, 51.7% of patients on the average weekly itch NRS, 50.0% on the worst weekly itch NRS, and 68.7% on the DLQI. Relative to the dupilumab-experienced cohort, the dupilumab-naïve patients showed markedly improved outcomes [median MCIDs of 65.6% v 48.4% on sleep NRS; 59.5% v 44.4% on average weekly itch NRS; 61.4% v 39.6% on worst weekly itch NRS; 61.4% v 35.3% on PO-SCORAD; and 75.6% v 61.9% on DLQI]. Conclusions This 6-month interim analysis shows that tralokinumab improved quality of life outcomes related to itch, sleep, and treatment satisfaction when used either in dupilumab-naïve or in dupilumab-experienced patients. These patients will continue to be followed for up to 52 weeks of treatment with tralokinumab.
531 - Physician-assessed effectiveness and patient-reported outcomes in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOSTAD multinational prospective observational study
Authors: Silvia M Ferrucci, Piergiacomo Calzavara-Pinton, Dédée F Murrell, Anne-Claire Fougerousse, Iva Karlova, Hilde Lapeere, Gregor Holzer, Mona Al-Ahmad, Chia-Yu Chu, Caterina Foti, Bibiana Pérez-García, Jiangming Wu, Marius Ardeleanu, Kwinten Bosman
Journal: British Journal of Dermatology (2024)

Abstract Introduction The GLOBOSTAD study aims to assess the extended real-world effectiveness of dupilumab in patients with atopic dermatitis (AD) receiving dupilumab as part of their normal care. Objectives To report patient-reported outcomes and physician-­assessed AD clinical measures for evaluating disease characteristics, severity, and treatment effectiveness 1 year after initiating dupilumab treatment. Methods This 5-year, multinational, prospective, observational study (NCT03992417) enrolled patients aged ≥12 years with moderate-to-severe AD. Patients received dupilumab based on country-specific prescribing information. Assessments were performed at baseline, 3 months (± 1 month), 6 months (± 2 months), and 12 months (± 2 months). Data are reported as observed for enrollment/safety (N = 955; data cutoff: March 2023) and follow-up (N = 903) populations including 13 adolescent patients with AD (≥12 and &amp;lt;18 years old). Results In this study, 758/863/705 patients completed ≥1 follow-up assessment at 3 months/6 months/12 months, respectively. During the study the mean (standard deviation [SD]) Eczema Area and Severity Index (EASI; &amp;gt;21 = severe; ≤7 = mild/no disease) scores decreased from 25.1 (12.8) at baseline to 6.1 (8.0) at 3 months, 4.6 (6.4) at 6 months and sustaining throughout the observation period [12 months; 4.2 (8.4)]. Mean Patient-Oriented Eczema Measure (SD) improved from 19.7 (6.4) at baseline descending to 8.7 (6.6) at 3 months, 7.7 (6.0) at 6 months and 7.1 (5.8) at 12 months. A significant improvement was also observed in Dermatology Life Quality Index (DLQI) from 13.7 (7.1) to 5.3 (5.1) to 4.4 (4.4) to 3.9 (4.2); and children’s DLQI from 12.2 (6.2) to 2.7 (2.9) to 2.9 (3.0) to 4.8 (4.8) by the end of the 3, 6 and 12-months observational period respectively. Dupilumab-related adverse events were reported in 187 (20.8%) patients. Conclusions In a real-world scenario, the initiation of dupilumab treatment led to early and sustained improvements in AD outcome measures throughout the 1-year observational period. Safety data remained consistent with findings from previous studies.
Biocompatible Ferrofluid‐Based Millirobot for Tumor Photothermal Therapy in Near‐Infrared‐II Window (Adv. Healthcare Mater. 4/2024)
Authors: Yiming Ji, Xue Bai, Hongyan Sun, Luyao Wang, Chunyuan Gan, Lina Jia, Junjie Xu, Wei Zhang, Liang Wang, Yingchen Xu, Yaxin Hou, Yinyan Wang, Hui Hui, Lin Feng
Journal: Advanced Healthcare Materials (2024)
Engineered Microbial Nanohybrids for Tumor‐Mediated NIR II Photothermal Enhanced Ferroptosis/Cuproptosis and Immunotherapy (Adv. Healthcare Mater. 4/2024)
Authors: Yihang Ruan, Huilan Zhuang, Xuemei Zeng, Lili Lin, Xuechun Wang, Panpan Xue, Shan Xu, Qi Chen, Shuangqian Yan, Wei Huang
Journal: Advanced Healthcare Materials (2024)

workers design a nanobiohybrid for targeted and specific colon tumor therapy through PTT, cuproptosis, ferroptosis, and immunotherapy.The synergistic manner not only highly efficiently suppresses tumor growth but inhibits tumor relapse and metastasis.
Utility of allogeneic stem cell transplantation for adult <scp>Ph+ALL</scp> with complete molecular remission
Authors: Satoshi Nishiwaki, Isamu Sugiura, Shin Fujisawa, Yoshihiro Hatta, Yoshiko Atsuta, Noriko Doki, Shingo Kurahashi, Yasunori Ueda, Nobuaki Dobashi, Tomoya Maeda, Itaru Matsumura, Masatsugu Tanaka, Shinichi Kako, Tatsuo Ichinohe, Takahiro Fukuda, Shigeki Ohtake, Yuichi Ishikawa, Yasushi Miyazaki, Hitoshi Kiyoi
Journal: American Journal of Hematology (2024)

Abstract This study aimed to investigate the usefulness of allogeneic stem cell transplantation (allo‐SCT) for Philadelphia chromosome‐positive acute lymphoblastic leukemia (Ph+ALL) in the first complete remission (CR1) with complete molecular remission (CMR). We compared the outcomes between Ph+ALL patients who did or did not undergo allo‐SCT in CR1. We included patients enrolled in the prospective clinical studies in the tyrosine kinase inhibitor era conducted by the Japan Adult Leukemia Study Group, who achieved CMR within 3 months. A total of 147 patients (allo‐SCT: 101; non‐SCT: 46) were eligible for this analysis. In the multivariate analyses, allo‐SCT was significantly associated with both superior overall survival (OS) (adjusted hazard ratio (aHR): 0.54; 95% CI: 0.30–0.97; p = .04) and relapse‐free survival (RFS) (aHR: 0.21; 95% CI: 0.12–0.38; p &lt; .001). The 5‐year adjusted OS and RFS were 73% and 70% in the allo‐SCT cohort, whereas they were 50% and 20% in the non‐SCT cohort. Despite the higher non‐relapse mortality (aHR: 3.49; 95% CI: 1.17–10.4; p = .03), allo‐SCT was significantly associated with a lower relapse rate (aHR: 0.10; 95% CI: 0.05–0.20; p &lt; .001). In addition, allo‐SCT was also associated with superior graft‐versus‐host disease‐free, relapse‐free survival (aHR: 0.43; 95% CI: 0.25–0.74; p = .002). Propensity score‐matched analyses confirmed the results of the multivariate analyses. In patients who achieved CMR within 3 months, allo‐SCT in CR1 had superior survival and lower relapse compared with the non‐SCT cohort.
Metal–Phenolic Networks‐Reinforced Extracellular Matrix Scaffold for Bone Regeneration via Combining Radical‐Scavenging and Photo‐Responsive Regulation of Microenvironment
Authors: Zhiqing Liu, Tianlong Wang, Lei Zhang, Yiping Luo, Jinhui Zhao, Yixing Chen, Yao Wang, Wentao Cao, Xinyu Zhao, Bingqiang Lu, Feng Chen, Zifei Zhou, Longpo Zheng
Journal: Advanced Healthcare Materials (2024)

Abstract The limited regulation strategies of the regeneration microenvironment significantly hinder bone defect repair effectiveness. One potential solution is using biomaterials capable of releasing bioactive ions and biomolecules. However, most existing biomaterials lack real‐time control features, failing to meet high regulation requirements. Herein, a new Strontium (Sr) and epigallocatechin‐3‐gallate (EGCG) based metal–phenolic network with polydopamine (PMPNs) modification is prepared. This material reinforces a biomimetic scaffold made of extracellular matrix (ECM) and hydroxyapatite nanowires (nHAW). The PMPNs@ECM/nHAW scaffold demonstrates exceptional scavenging of free radicals and reactive oxygen species (ROS), promoting HUVECs cell migration and angiogenesis, inducing stem cell osteogenic differentiation, and displaying high biocompatibility. Additionally, the PMPNs exhibit excellent photothermal properties, further enhancing the scaffold's bioactivities. In vivo studies confirm that PMPNs@ECM/nHAW with near‐infrared (NIR) stimulation significantly promotes angiogenesis and osteogenesis, effectively regulating the microenvironment and facilitating bone tissue repair. This research not only provides a biomimetic scaffold for bone regeneration but also introduces a novel strategy for designing advanced biomaterials. The combination of real‐time photothermal intervention and long‐term chemical intervention, achieved through the release of bioactive molecules/ions, represents a promising direction for future biomaterial development.